Our CEO, Howard Lee, joined Nasdaq Trade Talks to discuss the economic potential that cannabis legalization can create through tax revenue and job creation.
Our CEO, Howard Lee, recently interviewed with Bloomberg Tax & Accounting. Howard commented that the pandemic is changing the outlook on legalization of THC, the active ingredient of cannabis products, not only when it comes to recovering tax revenue, but also when it comes to social justice issues. Read the full interview.
”SōRSE intends to collaborate with other researchers and product developers to study cannabinoids in other medical applications. Pascal will continue to pursue other non-cancer indications for PAS-393.
“This is an impressive step forward for both Pascal and SōRSE, and hopefully our product will be a significant help to patients,” commented Dr. Patrick Gray, CEO of Pascal Biosciences. “This will be the first clinical trial for each company, and we look forward to a long, fruitful relationship.”
About Pascal Biosciences Inc.
Pascal is a biotechnology company targeting innovative therapies for serious diseases, including COVID-19. Pascal is also developing treatments for cancer with targeted therapies for acute lymphoblastic leukemia and cannabinoid-based therapeutics. Pascal’s leading portfolio also comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. For more information, visit www.pascalbiosciences.com.
Pascal recently discovered the unique capacity of its cannabinoid drug, PAS-393, to reverse a common immune-evading strategy adopted by many metastatic cancers. Thus, treatment with PAS-393 may restore the ability of the immune system to recognize and eliminate cancer cells. This activity is especially important for immune checkpoint inhibitors, which depend upon immune recognition of cancer for their efficacy. Pascal is advancing PAS-393 as a combination therapy with checkpoint inhibitors for the 50% or more of cancer patients not currently helped by the checkpoint inhibitors.
About SōRSE Technology Corporation
SōRSE Technology Corporation is a water-soluble emulsion technology designed for product developers to provide consumers with a better, more consistent cannabinoid experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Its patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for infusing CBD and other functional ingredients into beverages, food items, topicals, and medical applications. SōRSE Technology currently powers more than 45 leading products in the CBD space.
SōRSE Technology Press:
Jon Lindsay Phillips
Reuters exclusive — On September 14th, SōRSE Technology announced the partnership with Pascal Biosciences Inc. to start an early stage study of a cannabis-based cancer therapy. Learn more about this collaboration.
Our Director of Product Development, Michelle Sundquist, was recently featured in Cannabis Investing News where she explains why “Cannabis Drinks Need the Right Strategy to Succeed.” Learn more.
In the Nibble’s recent blog, our Director of Research & Analytics, Donna Wamsley, talks about her background as a Flavorist, some of her best creations, and the process of flavor development. Learn more.
Our CSO Scott Riefler, recently interviewed with Cannabis Retailer on the shelf life of cannabis edibles. He went over key factors when evaluating its stability. Read the full interview.
Check out our partner, Mad Tasty’s feature in Fortune where founder, Ryan Tedder, dives into the lessons he’s learned during his first year operating Mad Tasty and how SōRSE Technology played a key role in the launch of the CBD beverages. Read the full article.
Our Director of Product Development, Michelle Sundquist, was featured in Food Business News where she comments on the CBD beverage marketplace. Learn more about Michelle’s insights and check out some of our other partners featured in this article.